Evaluating quality of life in esophageal cancer patients after chemoradiation
Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer
This study is trying to see how treatment with chemoradiation affects the quality of life for people with esophageal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT03712774 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life in patients with esophageal cancer who are undergoing neoadjuvant or definitive chemoradiation. Quality of life will be measured using standardized EORTC questionnaires, while also evaluating acute and late toxicities, functional outcomes, and oncological results. The study will track local and distant control, freedom from treatment failure, and overall survival, with planned correlations between patient and physician assessments of functional outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically proven esophageal cancer who are eligible for neoadjuvant or definitive chemoradiation.
Not a fit: Patients with distant metastases (except supraclavicular nodes), those receiving palliative treatment, or individuals with prior systemic treatment for esophageal cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life and treatment outcomes for patients with esophageal cancer undergoing chemoradiation.
How similar studies have performed: While this approach is observational, similar studies evaluating quality of life in cancer patients have shown promising results, indicating the potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes) * indication for neoadjuvant or definitive chemoradiation using either cisplatin/5-FU or carboplatin/paclitaxel with curative intent * age \>= 18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * Treatment with palliative intent * distant metastases (except supraclavicular nodes) * second malignancy * Prior systemic treatment for esophageal Cancer * Treatment in an interventional study
Where this trial is running
Munich, Bavaria
- Department of Radiation Oncology, University Hospital, LMU Munich — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Principal investigator: Falk Roeder, MD — Ludwig-Maximilians Universität München
- Study coordinator: Falk Roeder, MD
- Email: Falk.Roeder@t-online.de
- Phone: +49 89 4400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.